{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T10:03:47Z","timestamp":1790676227754,"version":"4.1.0"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.ejca.2021.04.030","type":"journal-article","created":{"date-parts":[[2021,6,2]],"date-time":"2021-06-02T20:21:54Z","timestamp":1622665314000},"page":"100-115","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["Prognostic factors of metastatic neuroendocrine carcinoma under first-line treatment with platinum etoposide with a focus on NEC score and Rb expression: Results from the multicentre RBNEC study of the Groupe d\u2019Etude des Tumeurs Endocrines (GTE) and the ENDOCAN-RENATEN network"],"prefix":"10.1016","volume":"152","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1276-3289","authenticated-orcid":false,"given":"Julien","family":"Hadoux","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9007-8869","authenticated-orcid":false,"given":"Christina","family":"Kanaan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0193-9058","authenticated-orcid":false,"given":"Alice","family":"Durand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9gol\u00e8ne","family":"Hescot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Hautefeuille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Cadiot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor","family":"Tauveron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine","family":"Laboureau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Do Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Walter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Petorin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8275-8741","authenticated-orcid":false,"given":"Odile","family":"Blanchet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Jannin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2331-0792","authenticated-orcid":false,"given":"Matthieu","family":"Faron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Leteurtre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6917-7686","authenticated-orcid":false,"given":"Marie-Christine","family":"Rousselet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliette J.","family":"Zakeyh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aude","family":"Marchal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Chatelain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0915-209X","authenticated-orcid":false,"given":"Cl\u00e9ment","family":"Beaulaton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Hervieu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Ducreux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1604-6823","authenticated-orcid":false,"given":"Jean-Yves","family":"Scoazec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Baudin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2021.04.030_bib1","first-page":"1770","article-title":"A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal","volume":"31","author":"Rindi","year":"2018","journal-title":"Mod Pathol Off J U S Can Acad Pathol Inc"},{"key":"10.1016\/j.ejca.2021.04.030_bib2","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1159\/000443172","article-title":"ENETS consensus guidelines for high-grade gastroenteropancreatic neuroendocrine tumors and neuroendocrine carcinomas","volume":"103","author":"Garcia-Carbonero","year":"2016","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.ejca.2021.04.030_bib3","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.annonc.2020.03.304","article-title":"Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Pavel","year":"2020","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"10.1016\/j.ejca.2021.04.030_bib4","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1038\/sj.bjc.6690325","article-title":"Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin","volume":"81","author":"Mitry","year":"1999","journal-title":"Br J Canc"},{"key":"10.1016\/j.ejca.2021.04.030_bib5","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/1097-0142(19910715)68:2<227::AID-CNCR2820680202>3.0.CO;2-I","article-title":"Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms","volume":"68","author":"Moertel","year":"1991","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2021.04.030_bib6","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1002\/cncr.28721","article-title":"Gastroenteropancreatic high-grade neuroendocrine carcinoma","volume":"120","author":"Sorbye","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2021.04.030_bib7","first-page":"158","article-title":"Poorly differentiated gastro-entero-pancreatic neuroendocrine carcinomas: are they really heterogeneous? Insights from the FFCD-GTE national cohort","volume":"79","author":"Walter","year":"2017","journal-title":"Eur J Cancer Oxf Engl 1990"},{"key":"10.1016\/j.ejca.2021.04.030_bib8","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1093\/annonc\/mds276","article-title":"Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study","volume":"24","author":"Sorbye","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2021.04.030_bib9","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1200\/JCO.2008.20.1061","article-title":"Phase III trial of irinotecan\/cisplatin compared with etoposide\/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124","volume":"27","author":"Lara","year":"2009","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.ejca.2021.04.030_bib10","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1093\/annonc\/mdt009","article-title":"Multicentre phase II study of cisplatin-etoposide chemotherapy for advanced large-cell neuroendocrine lung carcinoma: the GFPC 0302 study","volume":"24","author":"Le Treut","year":"2013","journal-title":"Ann Oncol Off J Eur Soc Med Oncol ESMO"},{"key":"10.1016\/j.ejca.2021.04.030_bib11","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s12032-018-1103-x","article-title":"Intravenous versus oral etoposide: efficacy and correlation to clinical outcome in patients with high-grade metastatic gastroenteropancreatic neuroendocrine neoplasms (WHO G3)","volume":"35","author":"Ali","year":"2018","journal-title":"Med Oncol Northwood Lond Engl"},{"key":"10.1016\/j.ejca.2021.04.030_bib12","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1159\/000497336","article-title":"Carboplatin in combination with oral or intravenous etoposide for extra-pulmonary, poorly-differentiated neuroendocrine carcinomas","volume":"109","author":"Frizziero","year":"2019","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.ejca.2021.04.030_bib13","article-title":"A consensus developed morphological re-evaluation of 196 high-grade gastroenteropancreatic neuroendocrine neoplasms and its clinical correlations","author":"Elvebakken","year":"2020","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.ejca.2021.04.030_bib14","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1158\/1078-0432.CCR-17-1921","article-title":"Molecular subtypes of pulmonary large-cell neuroendocrine carcinoma predict chemotherapy treatment outcome","volume":"24","author":"Derks","year":"2018","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"10.1016\/j.ejca.2021.04.030_bib15","first-page":"1421","article-title":"Pancreatic neuroendocrine carcinoma G3 may be heterogeneous and could be classified into two distinct groups","volume":"20","author":"Tanaka","year":"2020","journal-title":"Pancreatol Off J Int Assoc Pancreatol IAP Al"},{"key":"10.1016\/j.ejca.2021.04.030_bib16","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djw277","article-title":"Design and validation of the GI-NEC score to prognosticate overall survival in patients with high-grade gastrointestinal neuroendocrine carcinomas","volume":"109","author":"Lamarca","year":"2017","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2021.04.030_bib17","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1097\/PAS.0b013e3182417d36","article-title":"Small cell and large cell neuroendocrine carcinomas of the pancreas are genetically similar and distinct from well-differentiated pancreatic neuroendocrine tumors","volume":"36","author":"Yachida","year":"2012","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.ejca.2021.04.030_bib18","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nature14664","article-title":"Comprehensive genomic profiles of small cell lung cancer","volume":"524","author":"George","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.ejca.2021.04.030_bib19","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1158\/1078-0432.CCR-15-2946","article-title":"Next-generation sequencing of pulmonary large cell neuroendocrine carcinoma reveals small cell carcinoma-like and non-small cell carcinoma-like subsets","volume":"22","author":"Rekhtman","year":"2016","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"10.1016\/j.ejca.2021.04.030_bib20","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1016\/j.humpath.2015.08.006","article-title":"Molecular characteristics of colorectal neuroendocrine carcinoma; similarities with adenocarcinoma rather than neuroendocrine tumor","volume":"46","author":"Takizawa","year":"2015","journal-title":"Hum Pathol"},{"key":"10.1016\/j.ejca.2021.04.030_bib21","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1200\/JCO.2005.04.8595","article-title":"Randomized phase III trial comparing irinotecan\/cisplatin with etoposide\/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer","volume":"24","author":"Hanna","year":"2006","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.ejca.2021.04.030_bib22","doi-asserted-by":"crossref","first-page":"4787","DOI":"10.1200\/JCO.2009.23.1548","article-title":"Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients with extensive-stage small-cell lung cancer","volume":"27","author":"Socinski","year":"2009","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.ejca.2021.04.030_bib23","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-16-3135","article-title":"Rb loss and KRAS mutation are predictors of the response to platinum-based chemotherapy in pancreatic neuroendocrine neoplasm with grade 3: a Japanese multicenter pancreatic NEN-G3 study","author":"Hijioka","year":"2017","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"10.1016\/j.ejca.2021.04.030_bib24","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1038\/s41467-018-03099-x","article-title":"Integrative genomic profiling of large-cell neuroendocrine carcinomas reveals distinct subtypes of high-grade neuroendocrine lung tumors","volume":"9","author":"George","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.ejca.2021.04.030_bib25","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13040643","article-title":"Biomarkers of response to etoposide-platinum chemotherapy in patients with grade 3 neuroendocrine neoplasms","volume":"13","author":"Lacombe","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.ejca.2021.04.030_bib26","series-title":"WHO classification of tumours editorial board","article-title":"Classification of neuroendocrine neoplasms of the digestive system","author":"Klimstra","year":"2019"},{"key":"10.1016\/j.ejca.2021.04.030_bib27","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"1990","journal-title":"Eur J Cancer Oxf Engl"},{"key":"10.1016\/j.ejca.2021.04.030_bib28","year":"2018"},{"key":"10.1016\/j.ejca.2021.04.030_bib29","first-page":"473","article-title":"Digestive Neuroendocrine Neoplasms (NEN): French Intergroup clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, GTE, RENATEN, TENPATH, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFR)","volume":"52","author":"de Mestier","year":"2020","journal-title":"Dig Liver Dis Off J Ital Soc Gastroenterol Ital Assoc Study Liver"},{"key":"10.1016\/j.ejca.2021.04.030_bib30","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1158\/1078-0432.CCR-16-0355","article-title":"Genomic profiling of large-cell neuroendocrine carcinoma of the lung","volume":"23","author":"Miyoshi","year":"2017","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"10.1016\/j.ejca.2021.04.030_bib31","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1002\/ijc.29835","article-title":"NOTCH, ASCL1, p53 and RB alterations define an alternative pathway driving neuroendocrine and small cell lung carcinomas","volume":"138","author":"Meder","year":"2016","journal-title":"Int J Canc"},{"key":"10.1016\/j.ejca.2021.04.030_bib32","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1126\/science.aat5749","article-title":"Reprogramming normal human epithelial tissues to a common, lethal neuroendocrine cancer lineage","volume":"362","author":"Park","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.ejca.2021.04.030_bib33","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1158\/1078-0432.CCR-13-1982","article-title":"Rb loss is characteristic of prostatic small cell neuroendocrine carcinoma","volume":"20","author":"Tan","year":"2014","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"10.1016\/j.ejca.2021.04.030_bib34","article-title":"ctDNA in neuroendocrine carcinoma of gastroenteropancreatic origin or of unknown primary: the CIRCAN-NEC pilot study","author":"Gerard","year":"2020","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.ejca.2021.04.030_bib35","first-page":"1259","article-title":"Divergent cyclin B1 expression and Rb\/p16\/cyclin D1 pathway aberrations among pulmonary neuroendocrine tumors","volume":"17","author":"Igarashi","year":"2004","journal-title":"Mod Pathol Off J U S Can Acad Pathol Inc"},{"key":"10.1016\/j.ejca.2021.04.030_bib36","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1053\/hupa.2000.19294","article-title":"Pulmonary atypical carcinoid: predictors of survival in 106 cases","volume":"31","author":"Beasley","year":"2000","journal-title":"Hum Pathol"},{"key":"10.1016\/j.ejca.2021.04.030_bib37","article-title":"Unique genomic landscape of high-grade neuroendocrine cervical carcinoma: implications for rethinking current treatment paradigms","volume":"4","author":"Eskander","year":"2020","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.ejca.2021.04.030_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.dld.2021.04.016","article-title":"FOLFIRINEC: a randomized phase II trial of mFOLFIRINOX vs platinum-etoposide for metastatic neuroendocrine carcinoma of gastroenteropancreatic or unknown origin","author":"Hadoux","year":"2021","journal-title":"Dig Liver Dis"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804921002768?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804921002768?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:31:58Z","timestamp":1760733118000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804921002768"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":38,"alternative-id":["S0959804921002768"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2021.04.030","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognostic factors of metastatic neuroendocrine carcinoma under first-line treatment with platinum etoposide with a focus on NEC score and Rb expression: Results from the multicentre RBNEC study of the Groupe d\u2019Etude des Tumeurs Endocrines (GTE) and the ENDOCAN-RENATEN network","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2021.04.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}